Business
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on
About this update from Oric Pharmaceuticals, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Lori Kunkel, M.D., to its board of directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization.\n “We are delighted to welcome Lori to our board of directors as ORIC embarks on this next phase of its evolution,” said Jacob Chacko, M.D., chief executive officer. Over a multi-decade career, Lori has made significant contributions as a clinician, academic and highly respected leader in the biotechnology community, and has played a key role in the development, approval and commercialization of multiple innovative oncology therapies. We look forward to her contributions and insights as we continue to advance our lead asset, ORIC-101, further into clinical development while ORIC-533 and our early stage pipeline progress toward the clinic.” Dr. Kunkel currently serves on the board of directors of Nurix Therapeutics, Maverick Therapeutics and Curis, and has served on the board of directors of Loxo Oncology, Amphivena, Harpoon Therapeutics and Tocagen. Previously, she served as acting Chief Medical Officer at Loxo Oncology, as Chief Medical Officer at Pharmacyclics and Proteolix, and in various senior clinical roles at Baxter Healthcare, Chiron, and Genentech. Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at the University of California, Los Angeles. Dr. Kunkel received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology. “ORIC Pharmaceuticals is making great strides in advancing its broad pipeline of novel therapies aimed at overcoming resistance in cancer, making this an incredibly exciting time to be joining the board,” said Dr. Kunkel. “I look forward to collaborating with the leadership team and my fellow board members to help ORIC advance its novel therapeutics a...